Borderline Personality Disorder Clinical Trial
Official title:
Psychoeducation of Borderline Patients
Verified date | September 2015 |
Source | Mclean Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Recent research suggests that BPD is a common, serious but treatable disorder with a better
than previously recognized prognosis. Despite these findings, many patients with BPD are not
given the borderline diagnosis by the mental health professionals treating them. It is also
true that many newly diagnosed borderline patients are not provided with up-to-date
information on the disorder even though psychoeducation has been found to be a useful form
of treatment for other serious psychiatric illnesses.
The investigators have conducted a preliminary randomized trial of psychoeducation for BPD
that found that those provided with immediate psychoeducation had a significantly greater
reduction in two core symptoms of BPD--general impulsivity and stormy relationships--than
those with delayed psychoeducation.
However, both instruction and assessment of change over time were conducted in person by
paraprofessionals. The importance of the current study is that it will allow the
investigators to develop and test the efficacy of an internet-based program of
psychoeducation for BPD that will be both cost efficient and easy to disseminate widely,
particularly to underserved populations.
Status | Completed |
Enrollment | 80 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Female - Ages 18 to 30 - Meets criteria for Borderline Personality Disorder - Intelligence Quotient must be 71 or higher Exclusion Criteria: - Males - Schizophrenia - Schizoaffective Disorder - Bipolar I - Serious Substance Use Disorder - Subjects cannot be in treatment at baseline |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | McLean Hospital | Belmont | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Mclean Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sheehan Disability Scale | A self-report measure used to assess psychosocial impairment | Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Other | Weissman's Social Adjustment Scale | A self-report measure used to assess psychosocial impairment | Change from baseline through weeks 4,8,12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Other | Clinically Useful Depression Outcome Scale | A self-report designed to assess sensitivity to change in depression symptoms | Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Other | Clinically Useful Anxiety Outcome Scale | A self-report designed to assess sensitivity to change in anxiety symptoms | Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Primary | Zanarini Rating Scale for Borderline Personality Disorder | A dimensional self-report measure of the nine DSM-IV symptoms of BPD | Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Secondary | Borderline Evaluation of Severity over Time | A self-report that measures change in severity of borderline psychopathology | Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Active, not recruiting |
NCT04587518 -
Five Factor Model Treatment for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Completed |
NCT03677037 -
The Short-Term MBT Project
|
Phase 3 | |
Not yet recruiting |
NCT05989529 -
Delving Into Borderline Personality Disorder Clinical Trial Experiences
|
||
Completed |
NCT02518906 -
Evaluation of AIT Study
|
N/A | |
Completed |
NCT02068326 -
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT02108990 -
Acetaminophen and Social Processes
|
Phase 2 | |
Not yet recruiting |
NCT01683136 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
|
N/A | |
Completed |
NCT02988037 -
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study
|
N/A | |
Completed |
NCT01635556 -
Evaluation of a Modified Dialectical Behavior Therapy Program
|
N/A | |
Completed |
NCT02397031 -
Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder
|
N/A | |
Terminated |
NCT01212588 -
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
|
Phase 2 | |
Terminated |
NCT01103180 -
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
|
Phase 2 | |
Terminated |
NCT00539188 -
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
|
Phase 2 | |
Recruiting |
NCT05398627 -
Neurofeedback for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT03994510 -
SHame prOpensity in bOrderline Personality Disorder
|
N/A | |
Recruiting |
NCT06005129 -
Personality Change Study for Borderline Personality Disorder
|
N/A |